Physician profile
Daniel Lee Downing
NPI 1134664691
$3,288.49
in general payments reported to CMS, 2019-2025
25 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $765 · 2024: $1,051 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $689.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $569.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $498.53 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $193.62 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $182.78 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $150.29 | 2024-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $114.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $106.30 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $105.51 | 2023-2025 | |
| Edwards Lifesciences Corporation | $100.47 | 2025 | Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company LTD. | $87.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.22 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $81.63 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $60.69 | 2025 | |
| Amgen INC. | $52.58 | 2024-2025 | Otezla, Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $41.89 | 2025 | |
| Medtronic, INC. | $33.34 | 2022 | |
| Astellas Pharma US INC | $23.54 | 2025 | Veozah |
| Amarin Pharma, INC. | $22.03 | 2022 | |
| Sanofi Pasteur INC. | $17.36 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.87 | 2022 | |
| Corcept Therapeutics | $14.52 | 2025 | Korlym |
| Viatris Specialty LLC | $13.77 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.08 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $12.70 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.